|

Loncastuximab tesirine Clinical Trials

6 actively recruiting trials across 5 locations

-1 trial since June 2026

Also known as: ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Lonca, Loncastuximab Tesirine-lpyl +5 more

Pipeline

Phase 1: 2Phase 2: 3Phase 2/3: 1

Top Sponsors

  • ADC Therapeutics S.A.2
  • University of Birmingham1
  • M.D. Anderson Cancer Center1
  • Juan P. Alderuccio, MD1
  • City of Hope Medical Center1

Indications

  • Cancer6
  • B-Cell Non-Hodgkin Lymphoma2
  • Relapsed B-Cell Non-Hodgkin Lymphoma1
  • Refractory B-Cell Non-Hodgkin Lymphoma1
  • Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.